After half-dose ticagrelor (loading dose 90mg, and then 45mg bidpo.) treatment for 3 days, the platelet aggregation is effectively inhibited by light transmission aggregometry method and thromboela-stogram.
planned to undergo PCI recently
planned to DAPT for 1 year after PCI

NCT03381755_inc_T1
Multiplier
half-dose
NCT03381755_inc_T2
Drug
ticagrelor
NCT03381755_inc_T3
Measurement
loading dose
NCT03381755_inc_T4
Value
90mg
NCT03381755_inc_T5
Multiplier
45mg bidpo.
NCT03381755_inc_T6
Scope
loading dose 90mg, and then 45mg bidpo.
NCT03381755_inc_T7
Temporal
treatment for 3 days
NCT03381755_inc_T8
Measurement
platelet aggregation
NCT03381755_inc_T9
Value
inhibited
NCT03381755_inc_T10
Qualifier
effectively
NCT03381755_inc_T11
Procedure
light transmission aggregometry
NCT03381755_inc_T12
Procedure
thromboela-stogram
NCT03381755_inc_T13
Scope
light transmission aggregometry method and thromboela-stogram
NCT03381755_inc_T14
Mood
planned to undergo
NCT03381755_inc_T15
Procedure
PCI
NCT03381755_inc_T16
Temporal
recently
NCT03381755_inc_T17
Scope
planned to undergo PCI
NCT03381755_inc_T18
Mood
planned to
NCT03381755_inc_T19
Procedure
DAPT
NCT03381755_inc_T20
Multiplier
for 1 year
NCT03381755_inc_T21
Temporal
after PCI
NCT03381755_inc_T22
Procedure
PCI
NCT03381755_inc_T23
Reference_point
PCI